Role of VI-RADS scoring in predicting tumor pathology
Not Applicable
- Conditions
- Health Condition 1: C67- Malignant neoplasm of bladder
- Registration Number
- CTRI/2022/05/042668
- Lead Sponsor
- KMC Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All the patients admitted in Urology department of Kasturba Hospital, Manipal with bladder mass on either any radiological investigation (ultrasonography, MRI) or diagnosed by cystoscopy (done anywhere else and referred to us without TURBT) and diagnosed with bladder cancer
Exclusion Criteria
1. Patients with metastasis
2. Patients with previous history of surgery, chemotherapy or radiotherapy for bladder tumor (primary bladder tumor or any pelvic tumor infiltrating bladder).
3. Patients in whom MRI was contraindicated/lack of consent.
4. Patients having non-transitional cell carcinoma (TCC) cancer, variant histology or carcinoma in situ (CIS) on HPE.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate and compare accuracy of VIRADS scoring for staging of bladder carcinoma preoperatively in comparison with postoperative histological grade.Timepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method 1. To verify the accuracy of the VI-RADS scoring system in predicting muscle-invasive bladder cancer and to explore its value in clinical application and management. <br/ ><br>2. To know the diagnostic performance of Vesical Imaging-Reporting and Data System (VIRADS) and to find a quantitative indicator for predicting muscle invasion of bladder cancer. <br/ ><br>3. To correlate bi-parametric scoring with conventional VIRADS in diagnostic accuracy.Timepoint: 4 weeks